Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Non-alcoholic fatty liver disease can lead to more severe, potentially fatal liver diseases, including cirrhosis.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.
A major randomized, double-blind study pitted Livalo (pitavastatin) against Pravachol (pravastatin).
AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 among those without cirrhosis is approved.
Olysio plus Norvir and two investigatory drugs led to a perfect cure rate among people with genotype 1b of hepatitis C in a recent small trial...
Researchers presented results from various studies on hepatitis C treatment and care at a medical conference in Seattle.
People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug inte...
AbbVieâ€™s combination tablet of ombitasvir, paritaprevir and ritonavir cured 95 percent of treatment-naive Japanese adults with genotype...
The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston included a trove of good news for people...
Recommended European Medicines Agency approve AbbVie’s ’3D’ regimen to treat genotypes 1 and 4 of hepatitis C, with or without ribavirin.
At the recent Conference on Retroviruses and Opportunistic Infections researchers reveled in promising new data on hepatitis C therapies.
Victrelis (boceprevir), Merck’s hepatitis C virus (HCV) protease inhibitor, should not be combined with the following Norvir (ritonavir)...
A 12-week, interferon-free combination of two experimental, once-daily drugs cured nine of 11 (82 percent) first-time treatment takers
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.